A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects

Hanmi Pharmaceutical Company Limited48 enrolled

Overview

An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics and safety of HCP1704 in healthy subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Health, Subjective

Interventions

HGP1810DRUG

HGP1810: Vildagliptin/Metformin

HCP1704DRUG

HCP1704: Vildagliptin/Metformin

Eligibility

Sex: ALLMin age: 19 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age 19\~55 years in healthy volunteers 2. BMI is more than 18.5 kg/m\^2 , no more than 24.9 kg/m\^2 3. Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing Exclusion Criteria: 1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system 2. Subjects who judged ineligible by the investigator

Locations (1)

Metro hospital

Anyang, South Korea